Introduction: The aim of the study was to report our experience in the use of Gamma Knife Stereotactic Radiosurgery (GKSTRS) for conjunctival squamous cell carcinoma (SCC) invading the orbit, as an alternative to exenteration surgery. Patients and Methods: Patients who had GKSTRS for conjunctival SCC invading the orbit but sparing the bone (AJCC eighth ed. T4a) with a minimum of 1-year follow-up were included. Treatment failure was defined as no decrease in tumour size 3 months post-treatment, or further growth during the follow-up period. Patients were followed up 3-monthly for 2 years and 6-monthly afterwards with a minimum of yearly MR Imaging of orbit. Results: Six patients met the inclusion criteria. MR imaging was used to identify the extent of orbital involvement of SCC. Stereotactic radiosurgery utilizing the Leksell Gamma Knife® Perfexion was delivered in a single session in which patients received 18–20 Gy to the 45–50% isodose. The median follow-up was 29 months. Four patients responded to the treatment and had no evidence of recurrence at their most recent follow-up. The treatment failed in 2 patients, in 1 of whom the tumour was larger and extended deeper into the orbit. The other patient developed a recurrence away from the treated area at 9 months, suggesting a multifocal disease. Both patients had poorly differentiated SCC. Conclusion: GKSTRS is a potential alternative to orbital exenteration surgery for conjunctival SCC extending into the anterior orbit in a selected group of patients refusing orbital exenteration or has a second blind eye. Nevertheless, the disease is more likely to recur than with exenteration surgery, hence lifelong monitoring and low threshold for surgical intervention or retreatment is prudent.

1.
Emmanuel
B
,
Ruder
E
,
Lin
SW
,
Abnet
C
,
Hollenbeck
A
,
Mbulaiteye
S
.
Incidence of squamous-cell carcinoma of the conjunctiva and other eye cancers in the NIH-AARP diet and health study
.
Ecancermedicalscience
.
2012
;
6
:
254
. .
2.
Lee
GA
,
Hirst
LW
.
Ocular surface squamous neoplasia
.
Surv Ophthalmol
.
1995
;
39
(
6
):
429
50
. .
3.
Sun
EC
,
Fears
TR
,
Goedert
JJ
.
Epidemiology of squamous cell conjunctival cancer
.
Cancer Epidemiol Biomarkers Prev
.
1997
;
6
(
2
):
73
7
.
4.
Shields
CL
,
Demirci
H
,
Karatza
E
,
Shields
JA
.
Clinical survey of 1643 melanocytic and nonmelanocytic conjunctival tumors
.
Ophthalmology
.
2004
;
111
(
9
):
1747
54
. .
5.
Erie
JC
,
Campbell
RJ
,
Liesegang
TJ
.
Conjunctival and corneal intraepithelial and invasive neoplasia
.
Ophthalmology
.
1986
;
93
(
2
):
176
83
. .
6.
Iliff
WJ
,
Marback
R
,
Green
WR
.
Invasive squamous cell carcinoma of the conjunctiva
.
Arch Ophthalmol
.
1975
;
93
(
2
):
119
22
. .
7.
Abt
NB
,
Zhao
J
,
Huang
Y
,
Eghrari
AO
.
Prognostic factors and survival for malignant conjunctival melanoma and squamous cell carcinoma over four decades
.
Am J Otolaryngol
.
2019 Jul-Aug
;
40
(
4
):
577
82
. .
8.
Lee
GA
,
Hirst
LW
.
Ocular surface squamous neoplasia
.
Surv Ophthalmol
.
1995
;
39
(
6
):
429
50
. .
9.
Tabbara
KF
,
Kersten
R
,
Daouk
N
,
Blodi
FC
.
Metastatic squamous cell carcinoma of the conjunctiva
.
Ophthalmology
.
1988
;
95
(
3
):
318
21
. .
10.
Bhattacharyya
N
,
Wenokur
RK
,
Rubin
PA
.
Metastasis of squamous cell carcinoma of the conjunctiva: case report and review of the literature
.
Am J Otolaryngol
.
1997
;
18
(
3
):
217
9
. .
11.
Shields
JA
,
Bakewell
B
,
Augsburger
JJ
,
Flanagan
JC
.
Classification and incidence of space-occupying lesions of the orbit. A survey of 645 biopsies
.
Arch Ophthalmol
.
1984
;
102
(
11
):
1606
11
. .
12.
Johnson
TE
,
Tabbara
KF
,
Weatherhead
RG
,
Kersten
RC
,
Rice
C
,
Nasr
AM
.
Secondary squamous cell carcinoma of the orbit
.
Arch Ophthalmol
.
1997
;
115
(
1
):
75
8
. .
13.
Amin
MBES
,
Greene
F
,
Byrd
DR
,
Brookland
RK
,
Washington
MK
,
Gershenwald
JE
, et al.
AJCC cancer staging manual
. 8th ed.
Berlin, Germany
:
Springer International Publishing: American Joint Commission on Cancer
;
2017
.
14.
Bartley
GB
,
Garrity
JA
,
Waller
RR
,
Henderson
JW
,
Ilstrup
DM
.
Orbital exenteration at the Mayo Clinic. 1967–1986
.
Ophthalmology
.
1989
;
96
:
468
73
.
15.
Miller
CV
,
Wolf
A
,
Klingenstein
A
,
Decker
C
,
Garip
A
,
Kampik
A
, et al.
Clinical outcome of advanced squamous cell carcinoma of the conjunctiva
.
Eye
.
2014
;
28
(
8
):
962
7
. .
16.
Gerring
RC
,
Ott
CT
,
Curry
JM
,
Sargi
ZB
,
Wester
ST
.
Orbital exenteration for advanced periorbital non-melanoma skin cancer: prognostic factors and survival
.
Eye
.
2017
;
31
(
3
):
379
88
. .
17.
Soysal
HG
,
Markoç
F
.
Invasive squamous cell carcinoma of the eyelids and periorbital region
.
Br J Ophthalmol
.
2007
;
91
(
3
):
325
9
. .
18.
Lommatzsch
P
.
Beta-ray treatment of malignant epithelial tumors of the conjunctiva
.
Am J Ophthalmol
.
1976
;
81
(
2
):
198
206
. .
19.
Lecuona
K
,
Stannard
C
,
Hart
G
,
Rice
J
,
Cook
C
,
Wetter
J
, et al.
The treatment of carcinoma in situ and squamous cell carcinoma of the conjunctiva with fractionated strontium-90 radiation in a population with a high prevalence of HIV
.
Br J Ophthalmol
.
2015
;
99
(
9
):
1158
61
. .
20.
Zehetmayer
M
,
Menapace
R
,
Kulnig
W
.
Combined local excision and brachytherapy with ruthenium-106 in the treatment of epibulbar malignancies
.
Ophthalmologica
.
1993
;
207
(
3
):
133
9
. .
21.
Ramonas
KM
,
Conway
RM
,
Daftari
IK
,
Crawford
JB
,
O'Brien
JM
.
Successful treatment of intraocularly invasive conjunctival squamous cell carcinoma with proton beam therapy
.
Arch Ophthalmol
.
2006
;
124
(
1
):
126
8
. .
22.
El-Assal
KS
,
Salvi
SM
,
Rundle
PA
,
Mudhar
HS
,
Rennie
IG
.
Treatment of invasive ocular surface squamous neoplasia with proton beam therapy
.
Eye
.
2013
;
27
(
10
):
1223
4
. .
23.
Ogawa
K
,
Toita
T
,
Kakinohana
Y
,
Adachi
G
,
Kojya
S
,
Itokazu
T
, et al.
Postoperative radiotherapy for squamous cell carcinoma of the maxillary sinus: analysis of local control and late complications
.
Oncol Rep
.
2001
;
8
(
2
):
315
9
. .
24.
Bowyer
JD
,
Sullivan
TJ
,
Whitehead
KJ
,
Kelly
LE
,
Allison
RW
.
The management of perineural spread of squamous cell carcinoma to the ocular adnexae
.
Ophthal Plast Reconstr Surg
.
2003
;
19
(
4
):
275
81
. .
25.
Rowe
J
,
Grainger
A
,
Walton
L
,
Silcocks
P
,
Radatz
M
,
Kemeny
A
.
Risk of malignancy after gamma knife stereotactic radiosurgery
.
Neurosurgery
.
2007
;
60
(
1
):
60
6
. discussion 5-6. .
26.
Finger
PT
.
Radiation therapy for orbital tumors: concepts, current use, and ophthalmic radiation side effects
.
Surv Ophthalmol
.
2009
;
54
(
5
):
545
68
. .
27.
Tyl
JW
,
Blank
LE
,
Koornneef
L
.
Brachytherapy in orbital tumors
.
Ophthalmology
.
1997
;
104
(
9
):
1475
9
. .
28.
Liang
ZG
,
Kusumawidjaja
G
,
Kazmi
F
,
Wee
JTS
,
Chua
MLK
.
Intensity-modulated radiotherapy for paranasal sinuses and base of skull tumors
.
Oral Oncol
.
2018
;
86
:
61
8
. .
29.
Bernier
J
,
Domenge
C
,
Ozsahin
M
,
Matuszewska
K
,
Lefèbvre
JL
,
Greiner
RH
, et al.
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer
.
N Engl J Med
.
2004
;
350
(
19
):
1945
52
. .
30.
Migden
MR
,
Khushalani
NI
,
Chang
ALS
,
Lewis
KD
,
Schmults
CD
,
Hernandez-Aya
L
, et al.
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial
.
Lancet Oncol
.
2020
;
21
(
2
):
294
305
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.